Abstract: The present invention relates to a ROCK inhibitor for use in the treatment or prevention of pulmonary edema associated with a virus infection. The present invention further concerns a use of an in vitro test system or the determination of inhibitors effectiveness in preventing or reducing apical sodium-potassium-ATPase (NKA) localisation in lung epithelial cells. Also provided is a method for detecting molecules effective in the prophylaxis and/or treatment of a pulmonary edema. Finally, the invention relates to a test system.

Abstract: This invention relates to oil refining, more particularly to a composition of a heavy fuel oil for use in marine power units and boiler plants. The fuel comprises, in percent by weight: an extract from the selective extraction of gas oil—(3-5), heavy catalytic cracking gas oil—(3-10), vacuum gas oil—(5-10), tar or topped residuum—(3-10), straight-run black oil—(10-20), viscosity breaking residue of heavy oil fractions—the rest. The selected combination of the components and their ratio may for example, result in a stable heavy fuel oil having improved viscosity properties. The inclusion of the above components into the fuel composition may also make it possible to expand the production of heavy fuel oils produced.

Abstract: Medicine, in particular medications for treating blood losses, hypoxic and ishemic states, for improving a blood oxygen supply and for preserving isolated perfused organs and tissues. The inventive medical emulsion of perfluororganic compounds includes rapidly excretable perfluororganic compounds such as perfluordecalin, perfluoractilbromide, a perfluoroganic additive embodied in the form of a mixture of perfluorinated tertiary amines and phospholipids in the form of a water-salt dispersion. The perfluordecalin and perfluoractilbromide are contained in the composition of the rapidly excretable perfluororganic compounds at a ratio ranging from 10:1 to 1:10. The mixture of perfluorinated tertiary amines is embodied in the form of the mixture of perfluorotpripropylamine and the co-products thereof: cis- and trans-isomers perfluor-1-propyl 3,4-dimethylpirrolidone and perfluor-1-propyl-4-methhylpiperidine.